Evidence map›Paper›PMID 42252305›Full record

ArticleActa pharmacologica Sinica2026

Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4/6 inhibitors in hormone receptor-positive breast cancers.

Shi-Yu Duan, Lin-Hui Zhai, Wei Zhang, Luo-Yi Chen, Rui-Xi Zhao, Xun Zou, Jia-Hui Ni, Xing-Long Jia, Tian-Yu Liu, Hang Fu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shi-Yu Duan *Department of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Lin-Hui Zhai *Translational Research Institute of Brain and Brain-like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
Wei Zhang *Department of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Luo-Yi ChenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Rui-Xi ZhaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Xun ZouState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Jia-Hui NiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Xing-Long JiaState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Tian-Yu LiuDepartment of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Hang FuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Min HuangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Min-Jia TanState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. mjtan@simm.ac.cn.
Cheng-Yu ChuDepartment of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China. chuchengyu@huashan.org.cn.
Yi-Ting JinDepartment of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China. clara_raky@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palbociclib, ribociclib, and abemaciclib, which are FDA-approved CDK4/6 inhibitors, constitute the standard first-line treatment for advanced hormone receptor-positive (HR

Indexed as

Antineoplastic AgentsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAminopyridinesBenzimidazolesCell Line, TumorCell ProliferationFemaleHumansPiperazinesProteomicsPurinesPyridinesabemaciclibAminopyridinesAntineoplastic AgentsBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesribociclibBreast cancerCDK4/6 inhibitorPhosphoproteomicsProteomics

Identifiers

PMID42252305
PMCPMC13487217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.